drugset / Trial / NCT00908349

Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

NCT00908349

Phase 3 Completed 214 enrolled Supernus Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR)

Timeline

Start
2009-06
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxcarbazepine Small molecule

Indications